Viking Global Investors
Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Viking Global Investors Information
Geographic Data
Address: 55 Railroad Avenue
City: Greenwich
State: CT
Zip: 06830
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
1,562,596Website Global Rank
16,000Website Monthly Traffic
Twitter Followers
Description
Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies. It is a global investment firm managing more than twenty billion in capital across long-short equity and long-only strategies. The firm was established in 1999 and is headquartered in Greenwich, Connecticut, with offices in New York City, Hong Kong, and London.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2021 | Global Processing Services | Private Equity Round | 300M |
| 3/2021 | Amunix | Series B | 117M |
| 2/2020 | Polaris Genomics | Seed Round | 2M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 3/2019 | Astarte Medical | Series A | 0 |
| 11/2021 | Cloudbeds | Series D | 0 |
| 3/2020 | AbCellera Biologics | Series A | 75M |
| 6/2015 | Credit Karma | Series E | 175M |
| 5/2020 | Ginkgo Bioworks | Series F | 70M |
| 5/2020 | AbCellera | Series B | 105M |
| 9/2019 | Ginkgo Bioworks | Series E | 0 |
| 10/2020 | Dock | Private Equity Round | 170M |
| 1/2021 | Color | Series D | 167M |
| 3/2020 | Impossible Foods | Series F | 500M |
| 4/2021 | Druva | Series H | 147M |
| 7/2020 | Mantra Bio | Series A | 25M |
| 5/2019 | Impossible Foods | Series E | 300M |
| 8/2019 | MedAnswers | Seed Round | 5M |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 1/2021 | Resilient Biotics | Series A | 7.2M |
| 3/2018 | Joyn Bio | Series A | 0 |
| 12/2017 | Ginkgo Bioworks | Series D | 0 |
| 4/2014 | Adaptive Biotechnologies | Series C | 5M |
| 10/2018 | Genomatica | Equity | 90M |
| 9/2017 | Joyn Bio | Series A | 0 |
| 5/2022 | Locus Biosciences | Series B | 0 |
| 3/2019 | Mediphage Bioceuticals | Convertible Note | 3.5M |
| 2/2022 | Cazoo | Post-IPO Debt | 0 |
| 4/2014 | Birchbox | Series B | 60M |
| 8/2019 | Motif | Series A | 27.5M |
| 6/2018 | Checkerspot | Seed Round | 5M |
| 7/2018 | Apeel Sciences | Series C | 70M |
| 10/2016 | Biome Makers | Seed Round | 2.2M |
| 5/2020 | Apeel Sciences | Series D | 0 |
| 12/2021 | DermBiont | Series A | 0 |
| 7/2016 | Roivant Sciences | Private Equity Round | 500M |
| 6/2021 | Motif | Series B | 0 |
| 8/2021 | Apeel Sciences | Series E | 0 |
| 11/2016 | Prospect Bio | Seed Round | 0 |
| 4/2019 | NextGen Jane | Series A | 9M |
| 6/2023 | Ecovative Design | Series E | 30M |
| 12/2019 | Iterable | Series D | 60M |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 8/2021 | Biome Makers | Series B | 0 |
| 10/2022 | Arctic Wolf | Convertible Note | 401M |
| 10/2020 | Arctic Wolf | Series E | 200M |
| 6/2019 | DermBiont | Series A | 0 |
| 8/2017 | Auris Health | Series D | 0 |
| 11/2018 | Auris Health | Series E | 0 |
| 10/2021 | Arcaea | Series A | 78M |
| 12/2017 | Zentalis Pharmaceuticals | Series B | 34M |
| 3/2021 | ID.me | Series C | 0 |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 4/2023 | ID.me | Series D | 0 |
| 9/2021 | AlphaSense | Series C | 180M |
| 4/2023 | AlphaSense | Series D | 100M |
| 4/2020 | Rallybio | Series B | 0 |
| 2/2017 | Xcell Biosciences | Series A | 12M |
| 10/2020 | Allonnia | Series A | 40M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 6/2009 | Vivacta | Venture Round | 4.5M |
| 9/2021 | Astarte Medical | Series A | 0 |
| 6/2021 | Clip | Series D | 250M |
| 8/2021 | Algen Biotechnologies | Seed Round | - |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 1/2020 | Color | Series D | 75M |
| 2/2020 | TruGenomix | Seed Round | 0 |
| 1/2023 | Mantra Bio | Series A | 9M |
| 4/2022 | Revenova | Venture Round | 0 |
| 10/2021 | Patina | Series A | 50M |
| 8/2017 | aTyr Pharma | Post-IPO Equity | 45M |
| 4/2014 | Adaptive Biotechnologies | Series D | 100M |
| 11/2020 | VastBiome | Seed Round | 4.5M |
| 7/2015 | Ginkgo Bioworks | Series B | 0 |
| 8/2021 | Talkdesk | Series D | 230M |
| 3/2020 | Cloudbeds | Series C | 0 |
| 11/2020 | Pharvaris | Series C | 80M |
| 10/2020 | LianBio | Series A | 0 |
| 2/2016 | Vitagene | Seed Round | 2M |
| 5/2019 | Inhibrx | Private Placement | 40M |
| 4/2019 | Checkerspot | Series A | 13M |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 5/2023 | Solarea Bio | Series B | 0 |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 10/2020 | Solarea Bio | Series A | 11.2M |
| 7/2021 | Arctic Wolf | Series F | 150M |
| 4/2020 | Affinivax | Series B | 120M |
| 8/2020 | PMV Pharmaceuticals | Series D | 70M |
| 6/2020 | HeadLight | Series B | 25.6M |
| 7/2020 | Talkdesk | Series C | 143M |
| 5/2022 | Dock | Private Equity Round | 0 |
| 10/2018 | Talkdesk | Series B | 100M |
| 10/2021 | Roivant Sciences | Post-IPO Equity | 0 |
| 7/2016 | Trace Genomics | Seed Round | 4M |
| 6/2021 | Antheia | Series B | 0 |
| 8/2021 | Pepgen | Venture Round | 0 |
| 6/2019 | Viela Bio | Series B | 0 |
| 1/2021 | Affinivax | Series C | 226M |
| 11/2018 | Roivant Sciences | Private Equity Round | 0 |
| 9/2022 | RayzeBio | Series D | 160M |
| 6/2017 | Yes To | Equity | 56M |
| 7/2021 | Genomatica | Series C | 0 |
| 12/2022 | Pearl Health | Series B | 0 |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 1/2022 | Xcell Biosciences | Series B | 27.5M |
| 2/2021 | Ensoma | Series A | 0 |
| 11/2021 | Color | Series E | 100M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 2/2018 | Boost Biomes | Seed Round | 2M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 6/2022 | AlphaSense | Series D | 225M |
| 1/2015 | Moderna Therapeutics | Series E | 0 |
| 12/2022 | Vector Biomed | Venture Round | 15M |
| 5/2020 | Checkerspot | Series B | 36M |
| 4/2021 | Lightmatter | Series B | 80M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 1/2023 | SetPoint Medical | Venture Round | 0 |
| 10/2021 | Groove | Series B | 45M |
| 1/2023 | Ensoma | Series B | 0 |
| 2/2016 | EpiBiome | Series A | 6M |
| 4/2021 | Icosavax | Series B | 0 |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 9/2015 | Impossible Foods | Series D | 108M |
| 8/2015 | Editas Medicine | Series B | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 6/2016 | Ginkgo Bioworks | Series C | 0 |
| 3/2021 | Ecovative Design | Series D | 60M |
| 4/2021 | Atlast Food | Series A | 40M |
| 7/2020 | VelosBio | Series B | 137M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 6/2021 | Iterable | Series E | 0 |
| 1/2022 | Cognism | Series C | 0 |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 10/2019 | Algen Biotechnologies | Pre Seed Round | - |
| 6/2019 | Druva | Series G | 0 |
| 11/2007 | Vivacta | Series B | 12M |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 12/2020 | Boost Biomes | Series A | 2M |
| 5/2023 | Lightmatter | Series C | 0 |
| 6/2022 | AlphaSense | Series D | 0 |
| 5/2022 | Locus Biosciences | Series B | 0 |
| 5/2022 | Dock | Private Equity Round | 0 |
| 4/2022 | Revenova | Venture Round | 0 |
| 2/2022 | Cazoo | Post-IPO Debt | 0 |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 1/2022 | Xcell Biosciences | Series B | 0 |
| 1/2022 | Cognism | Series C | 0 |
| 12/2021 | DermBiont | Series A | 0 |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
